Endometriosis Is NOT an Absolute Contraindication to Hormone Replacement Therapy
Postmenopausal women with a history of endometriosis can receive hormone replacement therapy (HRT), but you must prescribe combined estrogen-progestogen therapy or tibolone—never estrogen alone—even after hysterectomy. 1, 2, 3
Key Decision Framework
When HRT Should Be Offered
- Age <60 years or <10 years since menopause with bothersome vasomotor symptoms (VMS) and no other contraindications: proceed with combined HRT 1
- Premature or early surgical menopause (bilateral oophorectomy for endometriosis): HRT is particularly important until at least age 51 (natural menopause age) to prevent cardiovascular disease and osteoporosis 2
- Women with endometriosis history have higher baseline cardiovascular risk and lower bone density from prior surgeries and GnRH agonist use, making HRT benefits especially relevant 2
Absolute Contraindications (Same as General Population)
The Endocrine Society guideline lists standard contraindications that apply regardless of endometriosis history 1:
- Unexplained vaginal bleeding
- Active breast or endometrial cancer
- Recent stroke, TIA, MI, PE, or VTE
- Active liver disease
Endometriosis itself does not appear on this list. 1
Critical Prescribing Rule: Never Use Estrogen Alone
The single most important safety consideration is avoiding unopposed estrogen therapy. 2, 3, 4
- Estrogen-only HRT increases ovarian cancer risk nearly 3-fold (HR 2.898,95% CI 1.251-6.715) in women with endometriosis history 3
- Combined estrogen-progestogen therapy does not increase ovarian cancer risk compared to no HRT 3
- This rule applies even after hysterectomy—the concern is reactivation of residual endometriotic implants and potential malignant transformation, not endometrial protection 2, 4
Recommended Formulations
- Combined continuous estrogen-progestogen (preferred) 2, 4
- Tibolone (alternative with similar safety profile) 3, 4
Duration of HRT in women who developed ovarian cancer averaged 2.2 years, suggesting longer exposure may carry higher risk, though causality is unproven 3
Counseling Points Before Initiating HRT
Risk of Symptom Recurrence
- 2-4% of postmenopausal women experience endometriosis symptoms 5
- Recurrence of pelvic pain, dyspareunia, or new masses can occur with HRT, though absolute rates are low 6, 5, 4
- Instruct patients to report any return of pelvic pain, bleeding, or new symptoms immediately for evaluation 2, 5
Malignant Transformation Risk
- Theoretical concern exists for malignant transformation of residual endometriotic tissue, particularly endometriosis-associated ovarian cancers 6, 4
- This risk remains unproven and appears primarily associated with estrogen-only therapy 2, 3
- Any recurrent symptoms warrant rigorous evaluation including imaging and tumor markers 5
Quality of Life Benefits
- HRT effectively treats VMS, genitourinary syndrome of menopause, prevents bone loss, and reduces fracture risk 1
- Women should not be denied HRT solely because of endometriosis history, especially younger women with surgical menopause 2, 4
Common Pitfalls to Avoid
- Reflexively denying HRT to all women with endometriosis history—this is outdated practice 2, 4
- Prescribing estrogen-only therapy after hysterectomy in women with endometriosis—this is the single modifiable risk factor for ovarian cancer in this population 3
- Failing to counsel about symptom monitoring—any new pelvic symptoms require prompt evaluation, not reassurance 5
- Overlooking cardiovascular and bone health benefits in young women with surgical menopause—these women face elevated long-term morbidity without HRT 2
Special Consideration: Timing After Surgery
- If endometriosis was surgically excised, some experts suggest waiting 6-12 months before initiating HRT to reduce recurrence risk, though this is based on expert opinion rather than high-quality evidence 4
- For women with severe menopausal symptoms after bilateral oophorectomy, immediate HRT initiation is reasonable given the low absolute recurrence rate 2